Complications and Outcomes of Pouch Excision

May 14, 2019 updated by: Joel Bauer, Icahn School of Medicine at Mount Sinai

Ileal Pouch Salvage and Excision Operations: Indications, Complications and Outcomes

Procedure is offered today to most patients with chronic ulcerative colitis (CUC) or familial adenomatous polyposis (FAP) who are candidates for total proctocolectomy. While high rates of successful pouch surgery are reported, there is a significant long-term risk of pouch-related complications including ileo-anal anastomotic separation and stricture, pouch-perineal and pouch-vaginal fistula, pouchitis, pelvic sepsis, small bowel obstruction, and pouch dysfunction. Despite recent advances in treatment of these complications by medical and surgical means, these problems can still lead to pouch failure and pouch excision. The long-term rate of pouch excision is reported in large series to range from 5.3% to 24%. Moreover, the burden of quality of life impairment on patients with these complications is immense. Pouch excision operations are technically difficult with substantial morbidity. This study aimed to investigate the indications for pouch excision, the number of salvage operations prior to these excisions and complications of pouch excision surgeries.

Study Overview

Status

Completed

Detailed Description

Data Collection Data were collected by retrospective review of a single institution, single practice, prospectively maintained clinical database consisting of 1263 patients undergoing RPC with IPAA performed between 1981 and 2015. All cases of pouch excision were identified. The recorded data comprised of patient demographic details, pathologic diagnoses at the time of pouch formation and pouch excision, details on the surgical procedures performed including formation of the pouch, procedures performed attempting to salvage the pouch, excision of the pouch, and intraoperative and early (within 30 days after pouch excision surgery) complications.

Pouch Salvage Surgery The type and date of all pouch salvage surgical interventions performed under general anesthesia prior to pouch excision were documented and categorized. We documented and classified each trip to the operating room as a salvage encounter. Salvage procedures were defined as any surgical intervention performed to preserve the pouch and did not include procedures unrelated to the pouch, such as incisional hernia repairs. Operative salvage procedures included abscess drainage with incision and drainage of an abscess cavity and curettage of peri-pouch abscesses or fistula tracts. Fistula repair included any repair of peri-pouch fistulae including seton placement and advancement flap. Any transanal or abdominal repair or revision of the pouch including the pouch-anal anastomosis was classified as a pouch revision. Diversion was defined as the formation of any unplanned diverting loop ileostomy. Ileostomy reversal was defined as the restoration of continuity following an unplanned diversion. Loop ileostomies formed or reversed as part of a planned, staged RPC procedure were excluded. Other procedures included dilatation of the IPAA anastomosis with examination under anesthesia (EUA), formation of an entero-pouch bypass, and any resections of peri-pouch cysts or desmoids.

Indications for Pouch Excision Indications for pouch excision were based on documented preoperative clinical and histopathologic diagnoses. Pouch dysfunction was defined as stool incontinence with or without obstructed defecation. Pouchitis was separately defined as clinical symptoms of bleeding, cramping abdominal pain, anal discharge, tenesmus, urgency, and increased frequency of defecation [10]. Distinguishing between pouchitis and pouch dysfunction was based on the operating surgeon's preoperative clinical diagnosis rather than pathology. Septic complications included any pelvic, perineal, or perianal infection as a result of anastomotic dehiscence, abscess or persistent fistula arising from the pouch or IPAA. Other indications for pouch excision included cancer diagnosed from endoscopic biopsy or found at surgery. Pouch necrosis was defined as complete transmural ischemia of the pouch.

Summary Measures and Statistical Analyses. Summary statistics of continuous variables reported the mean and standard deviation (SD) and the median and interquartile range (IQR) as appropriate. Pouch survival was defined as the time between pouch formation and pouch excision surgeries. The rate of salvage encounters was calculated by the sum of all encounters in the operating room where the primary surgery was to salvage the pouch divided by the number of patients. Differences in pouch survival by indication for pouch excision were compared using log-rank test. Statistical significance was defined as P<0.05.

Excluded and Missing Data Missing data were not included in the analyses. One patient with FAP had her pouch formed in our center, sought care at an outside institution for her pouch excision and the indication for pouch excision was unknown. However, data collected at the time of pouch formation and salvage procedures performed on this patient prior to excision were available and included in the analyses. Another patient developed pouch necrosis two weeks after pouch formation surgery, the pouch was never functional, and this patient was not included in our analyses of pouch survival or salvage encounter rates.

Study Type

Observational

Enrollment (Actual)

94

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10029
        • Mount Sinai Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who have had an their pouch excised

Description

Inclusion Criteria:

  • All patients undergoing pouch excision

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with complications
Time Frame: Five years
Number of Participants with any post operative complication
Five years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joel J Bauer, MD, Icahn School of Medicine at Mount Sinai

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2015

Primary Completion (Actual)

April 1, 2017

Study Completion (Actual)

April 1, 2018

Study Registration Dates

First Submitted

May 14, 2019

First Submitted That Met QC Criteria

May 14, 2019

First Posted (Actual)

May 16, 2019

Study Record Updates

Last Update Posted (Actual)

May 16, 2019

Last Update Submitted That Met QC Criteria

May 14, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Diseases

3
Subscribe